[go: up one dir, main page]

MX2019005178A - Formulacion de complejo farmaceutica que comprende amlodipina, losartan y clortalidona. - Google Patents

Formulacion de complejo farmaceutica que comprende amlodipina, losartan y clortalidona.

Info

Publication number
MX2019005178A
MX2019005178A MX2019005178A MX2019005178A MX2019005178A MX 2019005178 A MX2019005178 A MX 2019005178A MX 2019005178 A MX2019005178 A MX 2019005178A MX 2019005178 A MX2019005178 A MX 2019005178A MX 2019005178 A MX2019005178 A MX 2019005178A
Authority
MX
Mexico
Prior art keywords
chlorthalidone
losartan
complex formulation
amlodipine
pharmaceutical complex
Prior art date
Application number
MX2019005178A
Other languages
English (en)
Inventor
Il Kim Yong
Hyun Park Jae
Soo Woo Jong
Taek Im Ho
Jun Cho Hyuk
Ee Lim Sol
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62076324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005178(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2019005178A publication Critical patent/MX2019005178A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una formulación de complejo farmacéutica que incluye amlodipina, losartán y clortalidona como ingredientes activos. La formulación de complejo farmacéutica de la presente invención que incluye amlodipina, losartán y clortalidona como ingredientes activos presenta excelentes características de disolución de los ingredientes activos, y tiene una alta uniformidad de contenido y estabilidad térmica. Por lo tanto, la formulación de complejo de la presente invención se puede usar como un agente profiláctico o terapéutico para enfermedades cardiovasculares, que tiene una excelente calidad y estabilidad térmica.
MX2019005178A 2016-11-03 2017-11-03 Formulacion de complejo farmaceutica que comprende amlodipina, losartan y clortalidona. MX2019005178A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160145518A KR101910902B1 (ko) 2016-11-03 2016-11-03 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
PCT/KR2017/012396 WO2018084627A2 (en) 2016-11-03 2017-11-03 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Publications (1)

Publication Number Publication Date
MX2019005178A true MX2019005178A (es) 2019-08-05

Family

ID=62076324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005178A MX2019005178A (es) 2016-11-03 2017-11-03 Formulacion de complejo farmaceutica que comprende amlodipina, losartan y clortalidona.

Country Status (12)

Country Link
KR (1) KR101910902B1 (es)
CO (1) CO2019004798A2 (es)
CR (1) CR20190264A (es)
DO (1) DOP2019000093A (es)
EA (1) EA201991107A1 (es)
EC (1) ECSP19038749A (es)
MX (1) MX2019005178A (es)
NI (1) NI201900046A (es)
PH (1) PH12019500778A1 (es)
SG (1) SG11201903145TA (es)
WO (1) WO2018084627A2 (es)
ZA (1) ZA201902718B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143914A (ko) * 2019-06-17 2020-12-28 주식회사유한양행 암로디핀 또는 이의 염 및 클로르탈리돈 또는 이의 염을 포함하는 다층 정제 형태의 약학 조성물
KR102900997B1 (ko) 2019-12-11 2025-12-22 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
KR20210152943A (ko) 2020-06-09 2021-12-16 한미약품 주식회사 암로디핀, 로사르탄 및 클로르탈리돈을 단층정에 포함하는 심혈관계 질환의 예방 또는 치료용 약제학적 복합제제
MX2022015607A (es) * 2020-06-09 2023-01-24 Hanmi Pharm Ind Co Ltd Preparacion farmaceutica de complejo, para prevenir o tratar enfermedades cardiovasculares, que compone de amlodipina, losartan y clortalidona en comprimido monocapa.
GEP20247647B (en) * 2020-12-18 2024-07-25 Daewoong Pharmaceutical Co Ltd Novel formulation for oral administration, comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl) sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
CN114705785B (zh) * 2022-04-21 2023-11-07 厦门泓益检测有限公司 一种植物油中氯酞酸的检测方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012329B1 (ru) * 2002-01-16 2009-08-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Способ получения практически аморфного телмисартана
WO2005014043A1 (en) * 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
KR100924236B1 (ko) * 2009-06-23 2009-10-29 충남대학교산학협력단 균일한 입도분포를 가지는 초미세입자의 신규한 제조방법 및 장치
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR101914930B1 (ko) * 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제

Also Published As

Publication number Publication date
CR20190264A (es) 2019-08-26
WO2018084627A2 (en) 2018-05-11
DOP2019000093A (es) 2019-09-30
KR20180049510A (ko) 2018-05-11
CO2019004798A2 (es) 2019-05-21
ECSP19038749A (es) 2019-06-30
SG11201903145TA (en) 2019-05-30
EA201991107A1 (ru) 2019-09-30
ZA201902718B (en) 2020-08-26
NI201900046A (es) 2019-10-11
WO2018084627A3 (en) 2018-07-26
PH12019500778A1 (en) 2019-07-24
KR101910902B1 (ko) 2018-10-24

Similar Documents

Publication Publication Date Title
PH12019500778A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
MX2023010042A (es) Polinucleotidos moduladores.
PH12018500057A1 (en) Substituted oxopyridine derivatives
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
PH12016502248A1 (en) Adenoassociated virus vectors for the treatment of lysosomal storage disorders
WO2016011306A3 (en) Terminal modifications of polynucleotides
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
MY189453A (en) 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
MX2018007319A (es) Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
IN2013MU03583A (es)
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
IN2014MU00916A (es)
IN2014CH00840A (es)
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
JO3435B1 (ar) تركيبة دوائية صلبة تحتوي على أملوديبن ولوسارتان
GR20150100035A (el) Φαρμακευτικο σκευασμα περιεχον απρεπιταντη και μεθοδος παρασκευης αυτου
WO2016073493A3 (en) Antifibrinolytic compounds
WO2016033549A3 (en) (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
PH12019500779A1 (en) Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
IN2014MU00495A (es)
GB2541348A (en) Clopidogrel for use in the treatment of benign prostatic hyperplasia
MX381207B (es) Uso de alcoholes de azucar en composiciones de tibolona